

# Index

## A

- Ablative procedures, 116
- Accelerated partial breast radiation therapy (APBI), 163
- Acellular dermal matrix (ADM), 87
- Acute pain
  - incidence and prevalence, 41–48
  - non-pharmacological treatment, 68
  - patient-related risk factors, 49
  - pharmacological treatment, 63, 68
  - radiation-related risk factors, 48
  - risk factors, 42–49
  - symptoms, 48
- Acute radiation skin toxicities
  - clinical findings
    - desquamation, 8–9
    - erythema, 8
  - diagnosis, 7, 8
  - grading systems, 8
  - occurrence, 7
  - prevention, 14–15
  - treatment, 15
- Adjuvant radiation therapy, 1, 39, 40
- American Institute for Cancer Research's Continuous Update Project, 184
- Anthracycline based chemotherapy, 135
- Arc therapy, 136
- Art therapy, 187
- Atrophy, 10
- Axillary lymph node dissection (ALND), 50, 106, 107, 109, 113

## B

- BCRL, *see* Breast cancer-related lymphedema
- Bio-impedance spectroscopy (BIS), 99, 100
- Breast cancer-related lymphedema (BCRL)

- clinical trials, 118
- definition, 101
  - absolute volume change relative to baseline, 102
  - absolute volume difference, 102
  - relative volume change, 102–104
- impairment-based diagnostic model, 98
- incidence, 97
- limb volume measurement
  - BIS, 100–101
  - circumferential tape measurement, 99
  - lymphoscintigraphy, 101
  - perometer, 99, 100
  - water volumetry, 99
- patient quality of life, 114
- precautionary recommendations, 117–118
- prospective screening model, 98
- radiation impacts, 108–112
- risk factors
  - ALND, 106
  - BMI, 105
  - chemotherapy, 108
  - edema, 105–106
  - lack of breast reconstruction, 107
  - local infection, 106
  - RLNR, 106
- symptoms, 113–114
- treatment
  - CDT, 114–115
  - exercise, 115
  - IPC, 115
  - surgical intervention, 116
  - treatment-related risk factors, 105
- Breast reconstruction, *see* Post-mastectomy radiation therapy (PMRT)
- Breath hold technique, 3

**C**

- Cancer Care Ontario's Supportive Care Guidelines Group (SCGG), 15
- Cancer pain, *see* Pain
- Cancer-related fatigue (CRF), 182
  - biological mechanisms
    - anemia, 28–29
    - cellular immunity, 28
    - inflammation, 26, 27
    - skin erythema, 27
  - definition, 23
  - predictors
    - behavioral symptoms, 30–31
    - clinical factors, 29–30
    - demographic factors, 29
    - hypofractionated radiation, 31
  - prevalence, 24–25
  - scales, 25–26
  - severity, 25
  - treatment
    - cognitive behavioral therapy, 32
    - exercise, 32
- Cardiotoxicity
  - constraints, 139–140
  - influencing factors
    - age, 134–135
    - anatomy, 132–133
    - cardiac risk factors, 134
    - systemic therapies, 135
    - treatment volume, 133–134
  - macrovascular changes, 128
  - minimizing methods, 136–139
  - population-based case-control study, 129
  - single-institution retrospective cohort studies, 130
  - subclinical cardiac changes, 132
- CDT, *see* Complete decongestive therapy
- Cellulitis, 106
- Central lung distance (CLD), 176
- Certified lymphedema therapist (CLT), 98, 114
- Chronic persistent pain
  - non-pharmacological treatment, 68
  - pharmacological treatment, 63, 68
  - prevalence, 50–54
  - risk factors, 50–54
- Clinical decision making, 1–3
- Cognitive-behavioral stress management (CBSM), 186
- Cognitive-behavioral therapy (CBT), 68, 186
- Commercial Claims and Encounters Database, 88
- Common Terminology Criteria for Adverse Event (CTCAE), 7–9, 160, 175, 177

- Complementary and alternative methods (CAM), 181
- Complete decongestive therapy (CDT), 114, 115
- Compression bandaging (CB), 115
- Congestive heart failure (CHF), 134
- Connective tissue disorders, 165
- Contralateral breast cancer, 146, 151–152, 154, 155
- CRF, *see* Cancer-related fatigue

**D**

- Dance movement therapy, 187
- Danish Breast Cancer Group (DBCG), 130–131
- Deep inferior epigastric perforator (DIEP), 84, 86
- Deep-inspiration breath hold (DIBH) technique, 136, 154, 179

**E**

- Early Breast Cancer Trialists Collaborative (EBCTC), 131
- EORTC 22881-10882 clinical trial, 160, 162, 164
- EORTC 22922/10925 clinical trial, 179
- EORTC AMAROS clinical trial, 113
- Erythema, 7, 8, 27
- Esophageal cancer, 146, 153
- Exercise interventions
  - fatigue, 182–183
  - lymphedema, 183
  - pain, 183
  - physical activity, 182
  - upper limb function, 183

**G**

- Genome-wide association studies (GWAS), 49
- Guided imagery, 187

**H**

- Herceptin, 135
- Hyperbaric oxygen, 74, 169
- Hyperpigmentation, 10

**I**

- Integrative medicine, 181, 182
- Intensity modulated radiation therapy (IMRT), 13, 136, 154, 163
- Intermittent pneumatic compression (IPC), 115

- International Association for the Study of Pain (IASP), 39
- International Commission on Radiological Protection, 13
- L**
- Late Effects of Normal Tissue, Subjective Objective Management and Analytic (LENT SOMA) scale, 160
- Late radiation skin toxicities
- clinical findings
    - atrophy, 10
    - hyperpigmentation, 10
    - morphea, 10–11
    - radiation recall, 11
    - RIF, 9
    - telangiectasia, 10
  - definition, 9
  - grading systems, 9
  - treatment, 15–, 16
- LPG technique, 165
- Lung cancer, 146–149, 178
- Lymphatic-venous anastomosis (LVA), 116
- Lymphology Association of North America (LANA), 114
- Lymphoscintigraphy, 101
- M**
- Mammography, 160
- Manual lymph drainage (MLD) technique, 115, 176
- MarketScan Health Risk Assessment Database, 88
- Mean heart dose, 129, 132, 133, 140
- Memorial Sloan Kettering, 86, 89, 90
- Mindfulness-based cognitive therapy (MBCT), 185
- Mindfulness-based stress reduction (MBSR), 185–186
- Morphea, 10–11, 16
- Multi-beam IMRT (m-IMRT), 154
- Multidimensional pain assessment, 59–61
- N**
- National Cancer Institute of Canada's MA.20 study, 1, 112–113, 179
- National Comprehensive Cancer Network (NCCN), 3, 23, 118
- National Lymphedema Network (NLN), 99, 117
- National Surgical Quality Improvement Program (NSQIP) database, 88, 89
- Nationwide Implant Sample Database, 84
- Neuropathic pain (NP), 41
- assessment, 61–63
  - medicines, 65–67
  - pain management, 68, 73
  - screening tools, 61
- Nociceptive pain, 40, 41
- Non-small cell lung cancer (NSCLC), 148
- Normal tissue complication probability models (NTCP), 163
- Nutritional interventions, 184–185
- P**
- Pain
- analgesics, 64
  - assessment, 58–63
  - definition, 39
  - etiology, 40–41
  - management, 63
  - non-pharmacological intervention, 69–73
  - pathophysiology, 40–41
- Partial breast irradiation, 138–139, 163
- Pentoxifylline (PTX), 15, 75, 165, 169
- Perometer, 99, 100
- Post-mastectomy radiation therapy (PMRT), 2, 152
- factors impacting toxicities, 83, 84
  - patient factors
    - bilateral implant reconstruction, 89
    - BMI, 88
    - prednisone use, 89
    - smoking, 88, 89
  - radiation planning factors
    - bolus, 91
    - chest wall boost, 91, 92
    - hyofractionation, 91
    - internal mammary nodes (IMNs)
      - coverage, 89–90
    - proton therapy, 91
  - surgical factors
    - acellular dermal matrix, 87
    - implant location, 87
    - incision location, 86
    - reconstruction timing, 84–86
- Pranic meditation, 186
- Prone positioning, 88, 138, 179
- Proton beam RT, 139
- Proton therapy, 91, 92, 163
- Pulmonary fibrosis, 176–177
- Pulmonary toxicity profile
- pulmonary fibrosis, 176–177
  - RP, 175–176
  - secondary lung cancers, 178

**R**

- Radiation dermatitis, 7–9, 11, 13, 15, 16
- Radiation-associated angiosarcoma, 149–151
- Radiation-induced brachial plexus neuropathy (RIBPN)
  - incidence/prevalence, 55–57
  - risk factors, 58
  - risk reduction, 74
  - symptoms, 55, 58
  - treatment interventions, 74–75
- Radiation-induced CD8 T-lymphocyte apoptosis (RILA), 164–165
- Radiation induced fibrosis (RIF), 9, 75
  - breast hypofractionation trials, 163
  - chemotherapy, 164
  - clinical manifestations, 159
  - clinical trials, 165–168
    - hyperbaric oxygen, 169
    - PTX/vitamin E, 165, 169
    - SOD, 169
  - connective tissue disorders, 165
  - development and expression, 160
  - EORTC 22881-10882 trial, 160
  - grading scales, 160
  - molecular markers, 164
  - occurrence, 159
  - patient-specific factors, 162, 164
  - physical therapy, 165
  - surgical intervention, 170
  - TGF-beta, 164
  - tissue compliance meter, 160
- Radiation-Induced Skin Reaction Assessment Scale (RISRA), 8
- Radiation pneumonitis (RP), 175
- Radiation recall, 11
- Radiation Therapy Oncology Group (RTOG), 8
- Radiotherapy Comparative Effectiveness (RADCOMP) study, 3, 139
- Radiotherapy Oncology Group (RTOG) scale, 7, 8, 160
- Regional lymph node radiation (RLNR), 106
  - BCRL incidence, 108–112
  - clinical indications, 112–113
- Relative volume change (RVC) equation, 102–103
- RP, *see* Radiation pneumonitis
- RTOG/EORTC Late Radiation Morbidity Scoring Schema, 9

**S**

- Second malignancies

- angiosarcoma, 149–151
  - breast tangent radiation technique, 154
  - contralateral breast cancer, 151–152
  - definition, 145–146
  - DIBH, 154–155
  - esophageal cancer, 153
  - lifetime attribute risk (LAR), 154
  - lung cancer, 147–149
  - radiotherapy vs. without radiotherapy, 146–147
  - Secondary lung cancers, 178
  - Single-photon emission computed tomography (SPECT), 101, 132
  - Skin toxicity
    - acute (*see* Acute radiation skin toxicities)
    - dysfunctional immune response, 12
    - impaired DNA damage pathways, 12
    - late (*see* Late radiation skin toxicities)
    - long-term skin outcomes, 16
    - non-radiation treatment characteristics, 13
    - optimized assessment tools, 16
    - patient-related factors, 11
    - radiation delivery
      - dosimetric factors, 13
      - fractionation, 13
      - treatment intent and delivery modality, 13
      - topical agents, 14, 15
  - Standard American diet (SAD), 184
  - Superoxide dismutase (SOD), 169
  - Surveillance, Epidemiology and End Results (SEER) database, 130, 131, 148, 150, 152, 153
  - Systemic therapies, 135, 164, 178
- T**
- Tamoxifen, 136, 164
  - Tangential IMRT (t-IMRT), 13, 154
  - Telangiectasia, 10, 16
  - Three-dimensional conformal RT (3D-CRT), 129, 130, 133, 139
  - Tissue compliance meter, 160, 162
  - Transforming growth factor-beta (TGF-beta), 159, 164
  - Transverse rectus abdominis musculocutaneous flap (TRAM), 84
  - Trastuzumab, 135

**U**

- Unidimensional pain scale, 59

**V**

Vascularized lymph node transfer (VLNT),  
116  
Vitamin E, 75, 165, 169  
Volumetric modulated arc therapy (VMAT),  
154

**W**

WHO analgesic ladder, 63, 68

Whole breast radiotherapy (WBI), 163, 164

Women's Environmental, Cancer and  
Radiation Epidemiology  
(WECARE) study, 151

Women's Health and Cancer Rights Act, 84

**Y**

Yoga therapy, 187